Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Risk of Infections With Ustekinumab and Tofacitinib Compared to Tumor Necrosis Factor α Antagonists in Inflammatory Bowel Diseases

Clinical Gastroenterology and Hepatology(2022)10.1016/j.cgh.2022.01.013Source: DataRank Database

Risk of Infections With Ustekinumab and Tofacitinib Compared to Tumor Necrosis Factor α Antagonists in Inflammatory Bowel Diseases is a research paper published in Clinical Gastroenterology and Hepatology (2022). On theSindex it has a DataRank of 0. It has been cited 41 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access41 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 5.89)OA: greenTopics (32)IDs (PubMed, PMC, OpenAlex)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Bharati D. Kochar,Tianxi Cai ORCID,Ashwin N. Ananthakrishnan ORCID,David Cheng

Live enrichment

PubMed:35066137 PMC:PMC9296690 OpenAlex:https://openalex.org/W4205781532

NIDDK NIH HHS

Grant: P30 DK043351

NIDDK NIH HHS

Grant: R01 DK127171

NLM NIH HHS

Grant: R01 LM013614

NIDDK NIH HHS

Grant: R21 DK127227

NIH

FWCI

5.89

Citation Percentile

1.0%

Citation Trend

2022

2023

2024

2025

2026

greenLicense: https://www.elsevier.com/legal/tdmrep-license

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9296690

publisherhttps://api.elsevier.com/content/article/PII:S1542356522000672?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1542356522000672?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.cgh.2022.01.013

Fields of Study

Inflammatory Bowel DiseaseSpondyloarthritis Studies and TreatmentsRheumatoid Arthritis Research and TherapiesBiological ProductsHumansInflammatory Bowel DiseasesPiperidinesPyrimidinesTumor Necrosis Factor InhibitorsTumor Necrosis Factor-alphaUstekinumab

MeSH Terms

UstekinumabTumor Necrosis Factor InhibitorsBiological ProductsHumansPiperidinesPyrimidinesTumor Necrosis Factor-alphaInflammatory Bowel Diseases

Keywords

TofacitinibUstekinumabInflammatory bowel diseaseInflammatory Bowel DiseasesTumor necrosis factor alphaUlcerative colitisTumor necrosis factor αVedolizumabSafetyPneumoniaInfectionsIbdBiologics